International News

Merck's Hepatitis C Drug Wins UK Cost Endorsement

From CDC National Prevention Information Network

March 12, 2012

The National Institute for Health and Clinical Excellence (NICE) on Friday recommended Merck & Co.'s new hepatitis C drug Victrelis (boceprevir) for use in Britain's state health service. Although it often shuns expensive new treatments on cost grounds, NICE noted that the significant improvements seen with Victrelis make it a cost-effective option. Victrelis costs £30,800 (US $48,109) for a 44-week regimen; it is designed to be administered with peginterferon-alfa and ribavirin, which add £11,000 (US $17,178) to the total. The draft guidelines are open for consultation before final approval.

Back to other news for March 2012

Adapted from:
Reuters
03.08.2012

Florida: Hepatitis C Targets Baby Boomers

Breakthroughs in HIV/HCV-Coinfection Treatment Shine at CROI 2012

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

No comments have been made.

Add Your Comment:

(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

What Would an HIV Cure Mean for You?

Condomless Anal Sex Rising in U.S. MSM With or Without HIV Infection

If We Act to Remove Structural, Behavioral and Social Barriers, We Can End the HIV Epidemic With the Medicines We Already Have

This Week in HIV Research: Immune System Differences Could Produce bNAbs; New HIV Infections Are No Longer Falling; and Zoledronic Acid May Prevent Bone Loss

What's the Next Game-Changer in HIV Treatment?

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.

MOST VIEWED ARTICLES

	What Would an HIV Cure Mean for You?
	Condomless Anal Sex Rising in U.S. MSM With or Without HIV Infection
	If We Act to Remove Structural, Behavioral and Social Barriers, We Can End the HIV Epidemic With the Medicines We Already Have
	This Week in HIV Research: Immune System Differences Could Produce bNAbs; New HIV Infections Are No Longer Falling; and Zoledronic Acid May Prevent Bone Loss
	What's the Next Game-Changer in HIV Treatment?

TheBodyPRO.com is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.